{"entity":{"id":"nct02462629","kind":"trial","name":"Study of BLZ-100 in Pediatric Subjects With CNS Tumors","aka":[],"tldr":"A phase 1 trial of Tozuleristide run by Blaze Bioscience Inc., completed.","summary":"Study of BLZ-100 in Pediatric Subjects With CNS Tumors is a phase 1 interventional study registered as NCT02462629 by Blaze Bioscience Inc., with 29 participants enrolled, started 2015-06. Conditions recorded: Central Nervous System Tumors. Interventions recorded: BLZ-100.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02462629","url":"https://clinicaltrials.gov/study/NCT02462629"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["blz-100"],"companies":["blaze-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02462629","phase":"1","setting":"A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors","sponsor":"Blaze Bioscience Inc.","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02462629/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"drug":[{"id":"blz-100","kind":"drug","name":"Tozuleristide","route":"/drugs/blz-100/"}],"company":[{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/"}]}}